Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting.
The aim of the present work was to investigate the biodistribution characteristics of PEG-coated polycyanoacrylate nanoparticles prepared by the nanoprecipitation/solvent diffusion method using the previously synthesized poly(MePEGcyanoacrylate-hexadecylcyanoacrylate) copolymer. It was observed that [14C]-radiolabeled PEGylated nanoparticles remained for a longer time in the blood circulation after intravenous administration to mice, compared to the non-PEGylated poly(hexadecylcyanoacrylate) (PHDCA) nanoparticles. Furthermore, hepatic accumulation was dramatically reduced, whereas a highly increased spleen uptake was shown. The PEGylation degree of the polymer seemed not to affect the in vivo behavior of the nanoparticles, whereas previously obtained in vitro data have shown a modification of plasma protein adsorption depending on the density of PEG at the surface of the particles. Moreover, the study of the in vitro cytotoxicity of the nanoparticles revealed that the PEGylation of the cyanoacrylate polymer reduced its toxicity. These results open up interesting perspectives for the targeting of drugs to other tissues than the liver.
Peracchia
M T
MT
Université Paris XI, Pharmacotechnie, UMR CNRS 8612 - 5, rue J.B. Clément, 92296, Châtenay-Malabry, France.
Fattal
E
E
Desmaële
D
D
Besnard
M
M
Noël
J P
JP
Gomis
J M
JM
Appel
M
M
d'Angelo
J
J
Couvreur
P
P
D000818:Animals; D002460:Cell Line; D003487:Cyanoacrylates / Q000493:pharmacokinetics*; D004337:Drug Carriers; D005260:Female; D007275:Injections, Intravenous; D051379:Mice; D011092:Polyethylene Glycols / Q000493:pharmacokinetics*; D011108:Polymers / Q000493:pharmacokinetics*; D013154:Spleen / Q000378:metabolism*; D014018:Tissue Distribution
D003487:Cyanoacrylates; D004337:Drug Carriers; D011108:Polymers; D011092:Polyethylene Glycols